JP2015509536A5 - - Google Patents

Download PDF

Info

Publication number
JP2015509536A5
JP2015509536A5 JP2014561029A JP2014561029A JP2015509536A5 JP 2015509536 A5 JP2015509536 A5 JP 2015509536A5 JP 2014561029 A JP2014561029 A JP 2014561029A JP 2014561029 A JP2014561029 A JP 2014561029A JP 2015509536 A5 JP2015509536 A5 JP 2015509536A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
cancer
methyl
pharmaceutically acceptable
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2014561029A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509536A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/029084 external-priority patent/WO2013134243A1/en
Publication of JP2015509536A publication Critical patent/JP2015509536A/ja
Publication of JP2015509536A5 publication Critical patent/JP2015509536A5/ja
Ceased legal-status Critical Current

Links

JP2014561029A 2012-03-07 2013-03-05 Rafキナーゼ阻害剤として有用な2−アミノ,6−フェニル置換ピリド[2,3−d]ピリミジン誘導体 Ceased JP2015509536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261607702P 2012-03-07 2012-03-07
US61/607,702 2012-03-07
PCT/US2013/029084 WO2013134243A1 (en) 2012-03-07 2013-03-05 2-amino, 6-phenyl substituted pyrido [2, 3 - d] pyrimidine derivatives useful as raf kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2015509536A JP2015509536A (ja) 2015-03-30
JP2015509536A5 true JP2015509536A5 (enExample) 2016-04-21

Family

ID=47884613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014561029A Ceased JP2015509536A (ja) 2012-03-07 2013-03-05 Rafキナーゼ阻害剤として有用な2−アミノ,6−フェニル置換ピリド[2,3−d]ピリミジン誘導体

Country Status (39)

Country Link
US (2) US8741911B2 (enExample)
EP (1) EP2850082B1 (enExample)
JP (1) JP2015509536A (enExample)
KR (1) KR20140129087A (enExample)
CN (1) CN104302646B (enExample)
AP (1) AP2014007899A0 (enExample)
AR (1) AR090151A1 (enExample)
AU (1) AU2013230146B2 (enExample)
BR (1) BR112014018528A8 (enExample)
CA (1) CA2863673A1 (enExample)
CL (1) CL2014002220A1 (enExample)
CO (1) CO7010837A2 (enExample)
CR (1) CR20140378A (enExample)
CY (1) CY1117846T1 (enExample)
DK (1) DK2850082T3 (enExample)
DO (1) DOP2014000200A (enExample)
EA (1) EA024824B1 (enExample)
EC (1) ECSP14017584A (enExample)
ES (1) ES2584387T3 (enExample)
HK (1) HK1202541A1 (enExample)
HR (1) HRP20160654T1 (enExample)
HU (1) HUE028095T2 (enExample)
IL (1) IL234052A (enExample)
IN (1) IN2014MN01575A (enExample)
LT (1) LT2850082T (enExample)
MA (1) MA37316B1 (enExample)
ME (1) ME02423B (enExample)
MX (1) MX2014010701A (enExample)
NZ (1) NZ627454A (enExample)
PE (1) PE20142338A1 (enExample)
PH (1) PH12014501986A1 (enExample)
PT (1) PT2850082T (enExample)
RS (1) RS54840B1 (enExample)
SG (1) SG11201404969YA (enExample)
SI (1) SI2850082T1 (enExample)
TN (1) TN2014000375A1 (enExample)
TW (1) TW201348233A (enExample)
UA (1) UA112340C2 (enExample)
WO (2) WO2013134243A1 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
TWI704151B (zh) 2014-12-22 2020-09-11 美商美國禮來大藥廠 Erk抑制劑
KR20190017767A (ko) * 2016-06-10 2019-02-20 노파르티스 아게 C-raf 억제제의 치료적 용도
EP3558979B1 (en) 2016-12-22 2021-02-17 Boehringer Ingelheim International GmbH Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
WO2018200981A1 (en) * 2017-04-28 2018-11-01 Quartz Therapeutics, Inc. Raf-degrading conjugate compounds
KR102746913B1 (ko) 2017-12-21 2024-12-24 베링거 인겔하임 인터내셔날 게엠베하 Sos1 억제제로서의 신규 벤질아미노 치환 피리도피리미디논 및 유도체
JP7161849B2 (ja) * 2018-01-24 2022-10-27 株式会社クラレ 第一級アミンの製造方法
AU2019215081B2 (en) 2018-01-31 2024-07-25 Deciphera Pharmaceuticals, Llc. Combination therapy for the treatment of gastrointestinal stromal tumors
CN111886006B (zh) 2018-01-31 2024-07-09 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
WO2020055760A1 (en) 2018-09-10 2020-03-19 Mirati Therapeutics, Inc. Combination therapies
PT3902547T (pt) 2018-12-28 2023-12-04 Deciphera Pharmaceuticals Llc Inibidores de csf1r para utilização no tratamento do cancro
IL285113B2 (en) 2019-02-06 2025-10-01 Lilly Co Eli History of 1-((2-(2,2,2-trifluoroethoxy)pyridin-4-yl)methyl)urea as KCNQ enhancers
EP3927433A1 (en) * 2019-02-18 2021-12-29 Genentech, Inc. Pyrido-pyrimidinyl compounds and methods of use
WO2020185812A1 (en) 2019-03-11 2020-09-17 Teva Pharmaceuticals International Gmbh Solid state forms of ripretinib
US10927111B2 (en) 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
HRP20231730T1 (hr) 2019-05-10 2024-05-10 Deciphera Pharmaceuticals, Llc Fenilaminopirimidin amidni inhibitori autofagije i postupci njihove primjene
SI3966206T1 (sl) 2019-05-10 2023-12-29 Deciphera Pharmaceuticals, Llc Heteroarilaminopirimidinski amidni zaviralci avtofagije in načini njihove uporabe
CA3143489A1 (en) 2019-06-17 2020-12-24 Deciphera Pharmaceuticals, Llc Aminopyrimidine amide autophagy inhibitors and methods of use thereof
WO2021030405A1 (en) 2019-08-12 2021-02-18 Deciphera Pharmaceuticals, Llc Ripretinib for treating gastrointestinal stromal tumors
MX2022001863A (es) 2019-08-12 2022-05-30 Deciphera Pharmaceuticals Llc Metodos para tratar los tumores del estroma gastrointestinal.
PH12022550976A1 (en) 2019-10-24 2023-09-25 Kinnate Biopharma Inc Inhibitors of raf kinases
CN119970649A (zh) 2019-12-30 2025-05-13 德西费拉制药有限责任公司 非晶型激酶抑制剂制剂及其使用方法
FI4084779T3 (fi) 2019-12-30 2024-12-16 Deciphera Pharmaceuticals Llc 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
US11407737B2 (en) 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
EP4237423B1 (en) 2020-11-02 2024-12-11 Boehringer Ingelheim International GmbH Substituted 1h-pyrazolo[4,3-c]pyridines and derivatives as egfr inhibitors
WO2022109001A1 (en) 2020-11-18 2022-05-27 Deciphera Pharmaceuticals, Llc Gcn2 and perk kinase inhibitors and methods of use thereof
AR124449A1 (es) 2020-12-22 2023-03-29 Qilu Regor Therapeutics Inc Inhibidores de sos1 y usos de los mismos
WO2022226261A1 (en) 2021-04-23 2022-10-27 Kinnate Biopharma Inc. Treatment of cancer with a raf inhibitor
US12065427B2 (en) 2021-04-29 2024-08-20 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating STING
WO2023099608A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
EP4441053A1 (en) 2021-12-01 2024-10-09 Boehringer Ingelheim International GmbH Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
US20250129096A1 (en) 2021-12-01 2025-04-24 Boehringer Ingelheim Int'l GmbH Corp. Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
IL312905A (en) 2021-12-01 2024-07-01 Boehringer Ingelheim Int Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN119013272A (zh) 2021-12-01 2024-11-22 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及其衍生物
EP4444429A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
EP4444430A1 (en) 2021-12-09 2024-10-16 Deciphera Pharmaceuticals, LLC Raf kinase inhibitors and methods of use thereof
US20250382288A1 (en) 2021-12-23 2025-12-18 Boehringer Ingelheim International Gmbh 8-aza quinazolines as brain-penetrant sos1-inhibitors
WO2023173017A1 (en) * 2022-03-09 2023-09-14 Blossomhill Therapeutics, Inc. Kras inhibitors for treating disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024089008A1 (en) 2022-10-26 2024-05-02 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
US20240174641A1 (en) 2022-10-26 2024-05-30 Boehringer Ingelheim International Gmbh Heterocyclic compounds capable of activating sting
CN120091997A (zh) 2022-10-26 2025-06-03 勃林格殷格翰国际有限公司 能够活化sting的杂环化合物
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
US20250019385A1 (en) 2023-05-30 2025-01-16 Boehringer Ingelheim International Gmbh Spirocyclic annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
GB2631397A (en) 2023-06-28 2025-01-08 Sevenless Therapeutics Ltd New treatments for pain
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
GB2633813A (en) 2023-09-21 2025-03-26 Sevenless Therapeutics Ltd New treatments for pain
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025083426A1 (en) 2023-10-20 2025-04-24 Sevenless Therapeutics Limited New treatments for pain
WO2025122952A1 (en) 2023-12-08 2025-06-12 Deciphera Pharmaceuticals, Llc Formulations of vimseltinib
WO2025137507A1 (en) 2023-12-22 2025-06-26 Regor Pharmaceuticals, Inc. Sos1 inhibitors and uses thereof
WO2025146548A1 (en) 2024-01-04 2025-07-10 Sevenless Therapeutics Limited Sos1 inhibitors useful to treat pain and cancer
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025210041A1 (en) 2024-04-03 2025-10-09 Boehringer Ingelheim International Gmbh Bicyclic benzylamido pyridine derivatives as sos1 inhibitors
WO2025231106A1 (en) 2024-05-01 2025-11-06 Deciphera Pharmaceuticals, Llc Csf-1r inhibitors and methods of use thereof
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
JPWO2004039782A1 (ja) * 2002-10-29 2006-03-02 麒麟麦酒株式会社 Flt3自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
US7897762B2 (en) 2006-09-14 2011-03-01 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of proliferative diseases
US8188113B2 (en) * 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
WO2011100319A1 (en) * 2010-02-09 2011-08-18 Exelixis, Inc. Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k and mtor in combination with autophagy inhibitors
AR090151A1 (es) * 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf

Similar Documents

Publication Publication Date Title
JP2015509536A5 (enExample)
HRP20160654T1 (hr) 1-(3,3-DIMETILBUTIL)-3-(2-FLUOR-4-METIL-5-(7-METIL-2-(METILAMINO)PIRIDO[2,3-d]PIRIMIDIN-6-IL)FENIL)UREA KAO INHIBITOR Raf KINAZE U LIJEČENJU RAKA
JP2014502638A5 (enExample)
JP2016522266A5 (enExample)
MD20140084A2 (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
IL292161B1 (en) New methylquinazolinone derivatives
HRP20160030T1 (hr) Derivati 6,7-dihidro-pirazolo[1,5-a]pirazin-4-ilamina koji su korisni kao inhibitori beta-sekretaze (bace)
CN107427516B8 (zh) 7-苄基-4-(2-甲基苄基)-2,4,6,7,8,9-六氢咪唑并[1,2-a]吡啶并[3,4-e]嘧啶-5(1h)-酮、其类似物、及其盐、以及它们用于治疗的方法
JP2014527042A5 (enExample)
JP2017519027A5 (enExample)
JP2018531274A5 (ja) 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗SIRPa化合物
JP2020510668A5 (enExample)
JP2014534269A5 (enExample)
MD20140072A2 (ro) Noi compuşi ai pirolului, procedeu de obţinere a lor şi compoziţii farmaceutice care îi conţin
IL295418B1 (en) Beta-d-2'-deoxy-2' alpha-fluoro-2'-bata-c-modified-2-different-n6-purine modified nucleotides for the treatment of hepatitis c virus
MD20140073A2 (en) New phosphate compounds, a process for their preparation and pharmaceutical compositions containing them
JP2012512158A5 (enExample)
JP2019510768A5 (enExample)
JP2012092103A5 (enExample)
HRP20120918T1 (hr) Aminopirazolski spoj
MX381000B (es) Cristales de compuesto azabicíclico.
JP2016537382A5 (enExample)
JP2017517538A5 (enExample)
HK1210771A1 (zh) 氮杂吲哚衍生物
JP2015516427A5 (enExample)